Category: CBDs
-
Yield Growth Corp (BOSS.C) secures hemp/oil facility, pays cash for it like a boss
In this era of companies looking to buy low value/high priced assets as expensively as possible to ensure ponzi-like market cap bumps, I can appreciate when a company finds a reasonably priced asset with real world revenues and functionality, that one can see for ones self if one takes a drive down Highway 1. I…
-
Westleaf (WL.V) brings prairie focus, first nations connections, novel ideas
I first heard about the Prairie Records cannabis retail business model mid last year. And my first thought upon seeing it was, this will never be allowed. Basically, instead of keeping everything behind glass and having consumers guess as to what weed they’re looking at and what it will do, Westleaf’s retail model is to…
-
Cannara Biotech (LOVE.C) makes MedMen look like a charitable institution
Cannara Biotech (LOVE.C) is a pig. I mean, okay. Pigs are actually kind of cool, they’re smart and bacon tastes good and they like a tummy rub, so Cannara is not actually a pig. But it is a trap for your money, and you should ideally not play with money traps because their sole purpose is,…
-
TGOD vs Wildflower: Underplaying your hand as opposed to overplaying it
Two news releases wafted past me yesterday that caused me to dig deeper than the words written on the page. This sometimes happens out of necessity – a company has to release news about a topic but can’t go into detail yet, or has bad news they don’t particularly want to run a highlighter over.…
-
Pure Global Cannabis (PURE.V) is up nearly double in a week – and still dirt cheap
When I write about Pure Global (PURE.V), people get confused because a) they’re always down, and b) they’re not a client company. They should be a running joke, right? Like an Instadose or a Namaste (N.V). Well if you bought in when I did, that’s even truer. It hit the markets on opening day around…
-
Instadose: Mistakes were made, but company makes commitment to oversight and improvement
[UPDATE]: The article below is one that we have stood behind from the day we posted it, and do to this day. What it shows is how a young company, one without the oversight of a more mature outfit, can make rash decisions and overpromise in a way that they hope will allow them to…
-
Canadian LPs rush to supply Germany’s constrained marijuana market (TGOD.T) (ASNT.T) (CXXI.C) (CROP.C)
Germany’s medical marijuana market is lucrative, and Canadian LPs want in. Thankfully, Germany also wants Canadian companies to show them what’s up. Germany’s Shortage While Germany, the hottest cannabis market in the EU, has legalized medical marijuana, the country is in a nation-wide shortage of cannabis for a number of bureaucratic reasons. As a result, Germany’s…
-
Chemesis (CSI.C): The hard moving global cannabis venture that gets it, even if you don’t
In talking to Chemesis (CSI.C) CEO Edgar Montero, one thing becomes abundantly clear: You can go ahead and grow all the marijuana you want, and he won’t begrudge you your opportunities. He just doesn’t think that’s going to change the world, nor be bait for a bigger player looking for acquisitions, nor be a means…
-
The hemp shift: Livewell (LVWL.V), Heritage (CANN.C), Ascent (ASNT.C), Isodiol (ISOL.C) lead the CBD chase
If you want CBD, which is the stuff in cannabis that makes you healthier but that doesn’t get you stoned, hemp has as much of the stuff as commercial cannabis does. But hemp doesn’t attract mind boggling valuations on the public markets. On the TSX, 20k sq ft of licensed cannabis in a greenhouse in…
-
Too professional: Pure Global (PURE.V) and the companies discounted because they’re actually building businesses
Had a conversation on the phone with Stephen Pynn, VP of Corporate Devs at Pure Global (PURE.V) this week that got me thinking. Pure has had an up and down run since landing on the public markets in July of this year. It ebbs and flows like the tides, never getting really beat up, but also…